Publication

Video

Supplements and Featured Publications

Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer
Volume1
Issue 1

Dr. Liu on ADCs Under Exploration in NSCLC

Stephen V. Liu, MD, discusses the expanding exploration of antibody-drug conjugates in non–small cell lung cancer.

Stephen V. Liu, MD, associate professor of medicine, Georgetown University, director of Thoracic Oncology, head of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, discusses the expanding exploration of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC). 

Although fam-trastuzumab deruxtecan-nxki (Enhertu) is the only ADC currently FDA approved in NSCLC, others are on the horizon, Liu says. Sacituzumab govitecan-hziy (Trodelvy) and datopotamab deruxtecan (DS-1062a), which are 2 ADCs that target Trop-2, have shown activity in patients who have received previous treatment, Liu says. These 2 ADCs are not biomarker driven, and they have shown clear signs of activity following prior therapies, Liu adds. It remains unknown if more benefit will be derived from these therapies in the frontline setting alone or in combination, Lie explains.

Tusamitamab ravtansine (SAR408701) is another ADC targeting CEACAM5 that has shown activity, Liu continues. Having a targetable biomarker can increase the chance for a beneficial response, Liu concludes. 

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity